title: Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin.
abstract: A double-blind, randomized, placebo-controlled study assessed the effects of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin in 30 healthy male volunteers.
  
  
  METHODS
  All subjects received phenytoin throughout the study. The dose of phenytoin was 100 mg three times daily; steady-state trough plasma phenytoin concentrations were determined on Day 6. Concurrent treatment with sertraline (16 subjects) or placebo (13 subjects) was initiated on Day 8 and continued throughout the study in those subjects whose trough plasma phenytoin concentrations were between 5 and 20 micrograms/mL. The dose of sertraline was increased from 50 to 200 mg/day over 7 days; the 200-mg dose was then administered for 10 days. The plasma phenytoin concentration-time profile was determined on Day 7 before the start of sertraline or placebo dosing and at the end of dosing on Day 24. Psychometric testing was done before and after dosing on Days 0, 7, and 24.
  
  
  RESULTS
  There were no significant differences between the sertraline group and the placebo group in the pharmacokinetic parameters of phenytoin. In addition, there was no indication that administration of phenytoin alone or concomitant administration of phenytoin and sertraline impaired cognitive function. Treatment-related side effects, primarily headache and nausea, were reported in 8 of 16 sertraline subjects and in 5 of 13 placebo subjects. Two subjects in the sertraline group withdrew because of side effects (rash), and 3 subjects in the placebo group withdrew because of side effects (rash and headache).
  
  
  CONCLUSIONS
  High dosages of setraline did not affect the pharmacokinetics or the pharmacodynamics of phenytoin in ths study performed in healthy volunteers.
authors.affiliation: Pfizer Central Research, Sandwich, Kent, United Kingdom.
authors.forename: W G
authors.initials: WG
authors.lastname: Rapeport
authors.forename: D C
authors.initials: DC
authors.lastname: Muirhead
authors.forename: S A
authors.initials: SA
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: Cross
authors.forename: K
authors.initials: K
authors.lastname: Wesnes
mesh_terms: D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003071:Cognition / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D010919:Placebos; D011581:Psychological Tests; D011597:Psychomotor Performance / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline
chemical_list: D015057:1-Naphthylamine; D010672:Phenytoin; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline